L'uso dei biomarcatori del liquido cerebrospinale nella diagnosi della malattia di Alzheimer: Un'indagine tra i laboratori italiani

Translated title of the contribution: The clinical use of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: An Italian survey

Giulia Sancesario, Manuela Gibellini, Sofia Toniolo, Simona Di Santo, Davide Chiasserini, Gaetano Bernardi, Lucilla Parnetti, Carlo Caltagirone, Sergio Bernardini

Research output: Contribution to journalArticle

Abstract

The use of cerebrospinal fluid (CSF) biomarkers amyloid b1-42 (Ab42), tau (T-tau), and phosphorylated tau (p-tau181) for the diagnosis of Alzheimer's Disease is limited to a restricted number of neurological centers. By a survey, we aimed to do a “selfie” of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs. The members of SIBioC and of the Piattaforma Italiana per le Malattie Neurodegenerative della Società Italiana di Neurologia per le Demenze (SINdem-ITALPLANED) together with other neurological clinics all over Italy have received an online questionnaire. Forty neurological centers require CSF analyses while 7/20 regions (35%) lack CSF laboratories. Standardization of pre-analytical procedures is present in 62.02% of laboratories and only 56% participate to International Quality Control Programs. There is no harmonization of the reported cut-offs. A cost-benefit analysis, with a program for standardization and harmonization should be promoted by Scientific Societies and National Health Services.

Original languageItalian
Pages (from-to)39-43
Number of pages5
JournalBiochimica Clinica
Volume42
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Cerebrospinal fluid
Biomarkers
Cerebrospinal Fluid
Alzheimer Disease
Standardization
Quality Control
Italy
Quality control
Cost benefit analysis
National Health Programs
Amyloid
Cost-Benefit Analysis
Dementia
Health
Surveys and Questionnaires

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical

Cite this

L'uso dei biomarcatori del liquido cerebrospinale nella diagnosi della malattia di Alzheimer : Un'indagine tra i laboratori italiani. / Sancesario, Giulia; Gibellini, Manuela; Toniolo, Sofia; Santo, Simona Di; Chiasserini, Davide; Bernardi, Gaetano; Parnetti, Lucilla; Caltagirone, Carlo; Bernardini, Sergio.

In: Biochimica Clinica, Vol. 42, No. 1, 01.01.2018, p. 39-43.

Research output: Contribution to journalArticle

Sancesario, Giulia ; Gibellini, Manuela ; Toniolo, Sofia ; Santo, Simona Di ; Chiasserini, Davide ; Bernardi, Gaetano ; Parnetti, Lucilla ; Caltagirone, Carlo ; Bernardini, Sergio. / L'uso dei biomarcatori del liquido cerebrospinale nella diagnosi della malattia di Alzheimer : Un'indagine tra i laboratori italiani. In: Biochimica Clinica. 2018 ; Vol. 42, No. 1. pp. 39-43.
@article{fdb14e0dc81b45298c87f8e916b5a709,
title = "L'uso dei biomarcatori del liquido cerebrospinale nella diagnosi della malattia di Alzheimer: Un'indagine tra i laboratori italiani",
abstract = "The use of cerebrospinal fluid (CSF) biomarkers amyloid b1-42 (Ab42), tau (T-tau), and phosphorylated tau (p-tau181) for the diagnosis of Alzheimer's Disease is limited to a restricted number of neurological centers. By a survey, we aimed to do a “selfie” of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs. The members of SIBioC and of the Piattaforma Italiana per le Malattie Neurodegenerative della Societ{\`a} Italiana di Neurologia per le Demenze (SINdem-ITALPLANED) together with other neurological clinics all over Italy have received an online questionnaire. Forty neurological centers require CSF analyses while 7/20 regions (35{\%}) lack CSF laboratories. Standardization of pre-analytical procedures is present in 62.02{\%} of laboratories and only 56{\%} participate to International Quality Control Programs. There is no harmonization of the reported cut-offs. A cost-benefit analysis, with a program for standardization and harmonization should be promoted by Scientific Societies and National Health Services.",
author = "Giulia Sancesario and Manuela Gibellini and Sofia Toniolo and Santo, {Simona Di} and Davide Chiasserini and Gaetano Bernardi and Lucilla Parnetti and Carlo Caltagirone and Sergio Bernardini",
year = "2018",
month = "1",
day = "1",
doi = "10.19186/BC_2018.007",
language = "Italian",
volume = "42",
pages = "39--43",
journal = "Biochimica Clinica",
issn = "0393-0564",
publisher = "CLAS International",
number = "1",

}

TY - JOUR

T1 - L'uso dei biomarcatori del liquido cerebrospinale nella diagnosi della malattia di Alzheimer

T2 - Un'indagine tra i laboratori italiani

AU - Sancesario, Giulia

AU - Gibellini, Manuela

AU - Toniolo, Sofia

AU - Santo, Simona Di

AU - Chiasserini, Davide

AU - Bernardi, Gaetano

AU - Parnetti, Lucilla

AU - Caltagirone, Carlo

AU - Bernardini, Sergio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The use of cerebrospinal fluid (CSF) biomarkers amyloid b1-42 (Ab42), tau (T-tau), and phosphorylated tau (p-tau181) for the diagnosis of Alzheimer's Disease is limited to a restricted number of neurological centers. By a survey, we aimed to do a “selfie” of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs. The members of SIBioC and of the Piattaforma Italiana per le Malattie Neurodegenerative della Società Italiana di Neurologia per le Demenze (SINdem-ITALPLANED) together with other neurological clinics all over Italy have received an online questionnaire. Forty neurological centers require CSF analyses while 7/20 regions (35%) lack CSF laboratories. Standardization of pre-analytical procedures is present in 62.02% of laboratories and only 56% participate to International Quality Control Programs. There is no harmonization of the reported cut-offs. A cost-benefit analysis, with a program for standardization and harmonization should be promoted by Scientific Societies and National Health Services.

AB - The use of cerebrospinal fluid (CSF) biomarkers amyloid b1-42 (Ab42), tau (T-tau), and phosphorylated tau (p-tau181) for the diagnosis of Alzheimer's Disease is limited to a restricted number of neurological centers. By a survey, we aimed to do a “selfie” of the use and diffusion of CSF biomarkers of dementia in Italy, the standardization of pre-analytical procedures, the harmonization of ranges, and the participation to Quality Control programs. The members of SIBioC and of the Piattaforma Italiana per le Malattie Neurodegenerative della Società Italiana di Neurologia per le Demenze (SINdem-ITALPLANED) together with other neurological clinics all over Italy have received an online questionnaire. Forty neurological centers require CSF analyses while 7/20 regions (35%) lack CSF laboratories. Standardization of pre-analytical procedures is present in 62.02% of laboratories and only 56% participate to International Quality Control Programs. There is no harmonization of the reported cut-offs. A cost-benefit analysis, with a program for standardization and harmonization should be promoted by Scientific Societies and National Health Services.

UR - http://www.scopus.com/inward/record.url?scp=85050512099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050512099&partnerID=8YFLogxK

U2 - 10.19186/BC_2018.007

DO - 10.19186/BC_2018.007

M3 - Articolo

AN - SCOPUS:85050512099

VL - 42

SP - 39

EP - 43

JO - Biochimica Clinica

JF - Biochimica Clinica

SN - 0393-0564

IS - 1

ER -